Increase in share capital

Oslo, 8 2013

Reference is made to the stock exchange announcement from DiaGenic ASA (the "Company") dated 29 April 2013 regarding the result in the subsequent repair offering.

The share capital increase pertaining to the subsequent offering has now been registered with the Norwegian Register of Business Enterprises. The new registered share capital of DiaGenic is NOK 40,799,365 divided into 81,598,730 shares, each with a nominal value of NOK 0.50, and each share gives the right of one vote at the Company's general meeting. The new shares will be immediately listed on Oslo Børs.

For further information, please contact:

Paul de Potocki, CEO, DiaGenic ASA, Phone +47 23 24 89 67

Ruben Ekbråten, CFO, DiaGenic ASA, Phone +47 23 24 89 53

****

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com